What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? [Yahoo! Finance]
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: Yahoo! Finance
The company is advancing efforts to develop psychedelic medicines targeting conditions like depression, bipolar II disorder, and other psychiatric and neurological disorders. Its flagship drug candidate GH001 is aimed at patients with treatment-resistant depression as well as those with bipolar II disorder and postpartum depression. What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? On March 10, Guggenheim boosted its price target on GH Research PLC (NASDAQ:GHRS) to $34 from $29 while reiterating a Buy rating on the stock. The equity research firm pointed to GH Research's 2025 financial results and clinical progress updates for its renewed bullish view on this psychedelic stock. GH Research PLC (NASDAQ:GHRS) reported its 2025 financial results and provided business updates on March 5. Regarding financials, the company said it spent $38.8 million on R&D and $22.0 million on general and administrative expenses in 2025. It finished the year with $280.7 million in ca
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDGlobeNewswire
- GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]Seeking Alpha
- GH Research (GHRS) was given a new $34.00 price target by Guggenheim.MarketBeat
- GH Research (GHRS) had its price target raised by Citizens Jmp from $39.00 to $42.00. They now have a "market outperform" rating on the stock.MarketBeat
- GH Research (GHRS) had its price target raised by Needham & Company LLC from $31.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
GHRS
Earnings
- 3/5/26 - Miss
GHRS
Sec Filings
- 3/25/26 - Form 6-K
- 3/16/26 - Form 6-K
- 3/5/26 - Form S-8
- GHRS's page on the SEC website